Data associated with the figures presented in this study are images, graphics, or tabulated data based on histopathologic analysis performed by a certified study pathologist or image analysis. Data for Tables 1 and 2 provide incidence, labeling scores, and p-values for statistical tests for uterine pathology and IHC expression by treatment group and timepoint or human endometrial tissue, as described in the Main Text file of the manuscript. Manual histopathologic data can be found in excel spreadsheets and are based on presence/absences (yes/no) of a pathologic finding and/or severity score as described in the manuscript (Fig. 1, 2, 3, 4). The image analysis data is based on the quantified area that is designated as “positive” for a particular immunohistochemical stain (Fig. 2, 4, and Suppl. Fig. S2). Supplementary Table 1 provides summary information on antibodies used for immunohistochemistry. Supplementary fig. S1 includes real time RT-PCR data standardized to a housekeeping gene and western blot data. This dataset is associated with the following publication: Suen, A., W. Jefferson, C. Wood, and C. Williams. SIX1 regulates aberrant endometrial epithelial cell differentiation and cancer trajectory. Molecular Cancer Research. American Association for Cancer Research, Inc., Philadelphia, PA, USA, 17(12): 2369-2382, (2019).

Background The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. Methods We have carried out a population-based study of 94 MBC cases collected in the UK. We screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the contribution of BRCA1 and BRCA2 to this risk. Results Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4 times (95% confidence interval [CI] = 1.4–4.0) the risk in the general population. No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8% (95% CI = 3–19). All the mutation carriers had a family history of breast, ovarian, prostate or pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives. Conclusion These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.

The data were gathered as a preliminary assessment of estrogenicity under base-flow conditions at over 100 sites (lakes and streams) throughout New Jersey followed by more targeted sampling of smallmouth bass at nine sites with varying levels of estrogenicity. In 2016, 102 sites (lakes and streams) for the preliminary estrogenicity assessment were selected utilizing compiled results of previous monitoring studies (chemical and biological), current sampling networks, and other areas of concern based on input from stakeholders. Discrete grab surface water samples were collected under base-flow conditions in the fall of 2016 and analyzed for levels of estrogenicity using a bioluminescent yeast screen. Water samples for estrogenicity were also collected from the nine health sites in April/May of 2017 in combination with fish sampling and again in November 2017 under base flow conditions. In the spring of 2017, 20 adult smallmouth bass were collected from each of the nine sites (two river and seven reservoir sites). Fish were collected by boat electroshocking, euthanized in the field, weighed, measured, a blood sample collected and a necropsy completed that included documenting any visible abnormalities and collecting tissues for histopathology. Plasma obtained from blood samples was analyzed for vitellogenin, a yolk precursor widely used as an indicator of estrogenic exposure in immature and male fishes. Five to seven sections of testes were processed for microscopic analyses, embedded in paraffin, sectioned at 5 µm, stained with hematoxylin and eosin. The presence of testicular oocytes was noted and the severity rated from 1 to 4 based on number and arrangement of oocytes.

전북대학교병원의 갑상선암_치료_호르몬제

the data set contains the figures and tables from the publication in addition to the means, standard errors of the mean and the sample sizes used in each group for every experiment. the data set also contains a description of the genes, their function and acronyms on the QPCR arrays used in the study. Finally, the dataset includes the histopathology reports on the uterine changes induced by the different chemicals and the criteria used by the pathologist to classify the estrogenic effects of the chemicals. This dataset is associated with the following publication: Conley, J., B. Hannas, V. Wilson, E. Gray, and J. Furr. A demonstration of the uncertainty in predicting the estrogenic activity of individual chemicals and mixtures from an in vitro estrogen receptor transcriptional activation assay (T47D-KBluc) to the in vivo uterotrophic assay using oral exposure. TOXICOLOGICAL SCIENCES. Society of Toxicology, 382-395, (2016).

Background Mutations in BRCA1 and BRCA2 account for approximately 50% of breast cancer families with more than four affected cases, whereas exonic mutations in p53, PTEN, CHK2 and ATM may account for a very small proportion. It was recently reported that an intronic variant of p53 - G13964C - occurred in three out of 42 (7.1%) 'hereditary' breast cancer patients, but not in any of 171 'sporadic' breast cancer control individuals (P = 0.0003). If this relatively frequent occurrence of G13964C in familial breast cancer and absence in control individuals were confirmed, then this would suggest that the G13964C variant plays a role in breast cancer susceptibility. Method We genotyped 71 familial breast cancer patients and 143 control individuals for the G13964C variant using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis. Results Three (4.2%; 95% confidence interval [CI] 0–8.9%) G13964C heterozygotes were identified. The variant was also identified in 5 out of 143 (3.5%; 95% CI 0.6–6.4%) control individuals without breast cancer or a family history of breast cancer, however, which is no different to the proportion found in familial cases (P = 0.9). Conclusion The present study would have had 80% power to detect an odds ratio of 4.4, and we therefore conclude that the G13946C polymorphism is not a 'high-risk' mutation for familial breast cancer.

ToxCast bioactivity data and model predictions for the estrogen receptor (ER) and androgen receptor (AR) pathways were obtained from the inks provided. This dataset is associated with the following publication: Lizarraga, L., J. Dean, J. Kaiser, S. Wesselkamper, J. Lambert, and J. Zhao. A Case Study on the Application of An Expert-driven Read-Across Approach in Support of Quantitative Risk Assessment of p,p’-Dichlorodiphenyldichloroethane. REGULATORY TOXICOLOGY AND PHARMACOLOGY. Elsevier Science Ltd, New York, NY, USA, 103: 301-313, (2019).